Enbiosis has made breakthrough in the treatment of irritable bowel syndrome (IBS), with 78% of the IBS patients who followed microbiome-based diets seeing symptoms improve dramatically.
Dr. Tarkan Karakan, a gastroenterology specialist who helped conduct the study, said: “We believe this achievement represents a significant step towards demonstrating the efficacy of personalised medical solutions. We examined intestinal flora of IBS sufferers before prescribing dietary regimes based on the findings. This novel approach to IBS treatment is the first time for microbiome modulation to be used to alleviate symptoms of gastrointestinal disorders.”
Enbiosis has also developed prebiotic prescriptions for IBS sufferers. “Not to be confused with probiotics, prebiotics are non-digestible compounds that aid the development of beneficial gut bacteria,” Özkan Ufuk Nalbantoğlu, Chief Technology Officer of ENBIOSIS, explained. “So along with providing dietary strategies based on sound nutrition, we also help IBS patients fortify their gut flora – thus easing their symptoms – through the judicious use of prebiotics.”
